Overview

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To characterize the safety and tolerability of nivolumab injected intralesionally in patients with high-risk oral premalignant lesions.
Phase:
Early Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Nivolumab